Ginkgo Bioworks Holdings, Inc. (DNA, Financial) experienced a significant decline in its stock price, dropping 5.04% to $7.92 per share with a trading volume of 354,386 shares and a turnover rate of 0.64%. The price fluctuation reached 6.59%.
The company's recent financial report revealed an operating revenue of $56.21 million and a net loss of $217 million, translating to an earnings per share of -$4.23. The gross profit stood at $25.16 million, and it has a negative price-to-earnings ratio of -0.44.
In terms of institutional ratings, 66% of the six institutions that rated the stock gave a "sell" recommendation, while 17% each suggested "buy" and "hold" ratings.
Within the biotechnology sector, where Ginkgo Bioworks is categorized, the overall growth was 0.02%. Noteworthy performances came from Apollomics Inc C/Wts 01/04/2028 (To Pur Ord), Coeptis Therapeutics Holdings Inc C/Wts 31/12/2024 (To Pur Com), and Creative Medical Technology Holdings, Inc. Meanwhile, Windtree Therapeutics, Inc., Aditxt, Inc., and Inhibikase Therapeutics, Inc. showed high activity with significant turnover rates.
Ginkgo Bioworks Holdings Inc operates as a cell programming platform, offering comprehensive services to tackle challenges in sectors such as food and agriculture, pharmaceuticals, and specialty chemicals. The business is divided into two segments: Foundry and Biosecurity, with the latter generating the majority of the revenue through data analytics and service fees.
